Information Provided By: 
Fly News Breaks for March 7, 2019
TEVA
Mar 7, 2019 | 05:36 EDT
UBS analyst Navin Jacob reinstated coverage of Teva Pharmaceutical with a Buy rating and $22 price target. The U.S. generic industry is on a path to recovery, Jacob tells investors in a research note, citing his firm's generic price erosion tracker data. The analyst sees 30% potential upside and views Teva's 2019 guidance as a "hiccup."
News For TEVA From the Last 2 Days
There are no results for your query TEVA
